IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 4343 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (167 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   Introduction
   History of IRIS
   Risk factors for...
   Criteria for Dia...
   Mechanism of IRIS
   Presentations of...
   Clinical Feature...
   Differential dia...
   Treatment of IRIS
   Prevention of IRIS
   References
   Article Tables

 Article Access Statistics
    Viewed10439    
    Printed195    
    Emailed11    
    PDF Downloaded1287    
    Comments [Add]    
    Cited by others 3    

Recommend this journal

 


 
REVIEW ARTICLE
Year : 2006  |  Volume : 72  |  Issue : 6  |  Page : 410-414

Immune reconstitution inflammatory syndrome


Department of Dermatology, Venereology and Leprosy, Grant Medical College and Sir J J Group of Hospitals, Mumbai, Maharashtra, India

Correspondence Address:
D G Saple
Department of Dermatology, Venereology and Leprosy, Grant Medical College, Mumbai - 400 008, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.29335

Rights and Permissions



How to cite this article:
Surjushe A U, Jindal S R, Kamath R R, Saple D G. Immune reconstitution inflammatory syndrome. Indian J Dermatol Venereol Leprol 2006;72:410-4

How to cite this URL:
Surjushe A U, Jindal S R, Kamath R R, Saple D G. Immune reconstitution inflammatory syndrome. Indian J Dermatol Venereol Leprol [serial online] 2006 [cited 2019 Oct 23];72:410-4. Available from: http://www.ijdvl.com/text.asp?2006/72/6/410/29335



  Introduction Top


Antiretroviral therapy (ART) strengthens the immune system and restores protective pathogen-specific immune responses. This results in decreased incidence of opportunistic infections (OI), decrease in the viral load and increase in the CD4 counts. With restoration of immunity, the body begins to fight aggressively against coexisting infection thereby causing atypical manifestations of opportunistic infections, which may cause severe inflammation in tissue. The constellation of clinical symptoms, signs or investigational parameters resulting from such inflammatory response has been variously called immune reconstitution inflammatory syndrome (IRIS) or immune restoration disease (IRD) or immune rebound illness.[1]

IRIS is defined as occurrence or worsening of clinical and/or laboratory parameters despite a favorable outcome in human immunodeficiency virus (HIV) surrogate markers (CD4 counts) and plasma viral load.[2] Both infective (clinical or subclinical) and noninfective conditions can act as triggering factors for precipitating IRIS.


  History of IRIS Top


After the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s, there were a lot of case reports and case-series dealing with IRIS[3],[4] and the name IRD was given for the phenomenon prior to 2000.[5] Joseph A. De Simone and colleagues from Thomas Jefferson University in Philadelphia were one of the first groups who attempted to define immune reconstitution syndrome in 2000.[6] They found that many HIV-positive people developed a spectrum of illnesses once they responded to HAART. They developed conditions such as Mycobacterium avium complex (MAC) infection and cryptococcal meningitis, at a time when their immune function was actually improving. Initially it was considered to be a Jarisch-Herxheimer or lepra-like reaction. Later it was found to be due to the restoration of immunity thereby eliciting hypersensitivity reaction to an existing microbe or antigen in the body. De Simone and his colleagues named this relatively uncommon phenomenon as immune reconstitution syndrome.[6]


  Risk factors for IRIS Top


IRIS occurs more frequently in some patients or in some situations. These include: a CD4 count below 50 cells/cmm prior to initiation of HAART,[7] a high viral load before initiation of therapy,[8] undetected presence of antigens of nonviable microorganisms (e.g., cryptococci and CMV), active or subclinical infection by opportunistic pathogens, initiation of ART in close proximity to the diagnosis and initiation of treatment for an OI,[9] use of cytokines such as IL-2 to treat HIV infection and genetic mutations of innate cytokines.


  Criteria for Diagnosis Top


Recently, French et al have laid down criteria so as to aid the diagnosis.[2] These are:

Major criteria

  1. Atypical presentation of 'opportunistic infections or tumors' in patients responding to antiretroviral therapy.
  2. Decrease in plasma HIV RNA level by at least 1log 10 copies/mL.


Minor criteria

  1. Increased blood CD4 T-cell count after HAART.
  2. Increase in immune response specific to the relevant pathogen, e.g., DTH response to mycobacterial antigens.
  3. Spontaneous resolution of disease without specific antimicrobial therapy or tumor chemotherapy with continuation of antiretroviral therapy.



  Mechanism of IRIS Top


Although the exact mechanism of IRIS is not known, it may be due to immunologic consequences of HAART such as increase in CD4 cell levels, along with an elevated CD8 cell count and an increased activity of cytokines like IL-2 and interferon-gamma.

De Simone and his colleagues noted that a decrease in HIV viral load might alter levels of interleukin 12 (IL-12), a mediator of anti-cryptococcal activity, resulting in meningitis symptoms. Guillaume Foulon and colleagues found that interleukin 2 (IL-2) and interferon-gamma appeared to be the important factors in two patients developing sarcoidosis as IRIS, as both cytokines are essential in the production of a granulomatous response.[10]


  Presentations of IRIS Top


The clinical features of IRIS differ according to the inflammatory or infective pathology that is responsible for causing it [Table - 1]. Briefly the various presentations include,

Noninfectious syndromes:

(i) With cutaneous involvement :
Papular urticaria, eosinophilic folliculitis, Sweet's syndrome, Reiter's syndrome, sarcoidosis, systemic lupus erythematosus, Peyronie's disease

(ii) Without cutaneous involvement : Autoimmune thyroiditis, Guillain-Barrι syndrome, myopathy, radiculopathy, acute porphyria, Non-Hodgkin's lymphomas, Castleman's disease

Infectious syndromes

Various infectious syndromes described in association with IRIS are mentioned in [Table - 1].


  Clinical Features of some common IRIS Top


The clinical manifestations of IRIS associated with some common OIs are elaborated below.

Tuberculosis and atypical mycobacterial infections[11],[12]

Tuberculosis (TB) as IRIS typically occurs one to six weeks after the patient begins ART. The signs and symptoms of tuberculous IRIS may include high fever, new or worsening lymphadenopathy (mediastinal or peripheral), worsening of pulmonary symptoms and infiltrates or new or increasing pleural effusion. Lymph node abscesses usually occur during the first weeks on HAART.

Extrapulmonary presentations may occur, including expanding central nervous system lesions, skin or visceral abscesses, osteomyelitis, nephritis, meningitis, hypercalcemia, hepatosplenomegaly, epididymo-orchitis, psoas abscess and bowel perforation.

In one study, four out of five patients, who had clinically developed atypical mycobacterial infections after HAART and significant improvements in CD4 T cell levels, showed a significantly increased MAC-specific T cell response in vitro , proving that this phenomenon is indeed caused by the unmasking of subclinical infections.

Cryptococcal meningitis[13]

Cryptococcal IRIS is usually seen within one week to 11 months after ART. In patients with or without previously diagnosed cryptococcal meningitis, presentation of cryptococcal IRIS typically includes fever, headache, lymphadenitis and meningitis. In cases of IRIS, the MRI usually shows choriomeningitis with significant enhancement in the choroid plexus. Cryptococcal antigen in the cerebrospinal fluid is positive, although culture remains negative.

Pneumocystis jiroveci pneumonia[14]

Immune reconstitution inflammatory syndrome may present as worsening pulmonary symptoms and high fever in patients who had been improving on PCP therapy or in patients with recent successful treatment of PCP. Chest X-ray may show worsening lung involvement and oxygen saturation or arterial blood gas measurements may show worsening hypoxia or alveolar-arterial oxygen gradient. PCP IRIS, in certain cases, may lead to fatal acute respiratory failure.

CMV[15]

CMV retinitis may be seen either in patients with a prior history of CMV retinitis or in patients with no previous evidence of retinitis while CMV vitritis and uveitis are seen exclusively in people with previous CMV retinitis infection who responded to ARV therapy.

CMV vitritis typically will present with acute onset of blurred vision and "floaters" caused by posterior segment inflammation. Ophthalmologic examination reveals numerous inflammatory cells in the vitreous humor. Symptoms usually resolve in one month without specific treatment and without any lasting visual effects.

CMV uveitis as IRIS may occur within months of ART initiation, but typically is a late complication; occurring about three years after patients begin ART. It often results in macular edema, epiretinal membrane formation and/or cataracts, which can lead to permanent vision loss and hence requires a high index of suspicion.


  Differential diagnosis Top


Failure of ART or toxicity, active opportunistic infection and failure of antimicrobial therapy are considered in the differential diagnosis.

Failure of ART can be ruled out with decrease in CD4 count, increase in viral load, along with clinical deterioration while active opportunistic infections can be ruled out by isolating the pathogens. The World Health Organization (WHO) made an important distinction between IRIS and clinical failure while on anti-HIV therapy.[16]
"Clinical failure is defined as clinical disease progression with development of an opportunistic infection or malignancy when the drugs have been given sufficient time to induce a protective degree of immune restoration. This needs to be differentiated from an immune reconstitution syndrome which can be seen within the first several weeks after the institution of therapy if a subclinical infection is present at baseline."[16]


  Treatment of IRIS Top


As of now, there are no standard guidelines for the treatment of IRIS and the following interventions are mostly based on published case reports and other anecdotal clinical evidence. Treatment includes continuation of primary therapy against the offending pathogen in order to decrease the antigenic load, continuation of effective HAART and judicious use of anti-inflammatory agents.[17]

  1. Milder IRIS: Continue HARRT, antimicrobial agents and nonsteroidal antiinflammatory drugs.
  2. Severe life-threatening IRIS: Needs oral prednisolone, approximately 1-2 mg/kg. The exact duration and dose of the steroid is variable and depends upon clinical severity. Sometimes the duration of the steroid therapy may extend to six months or one year. Consider discontinuation of HAART in case of severe life-threatening IRIS (e.g., encephalitis, ARDS, cerebritis and perilesional cerebral edema).


Patients with IRIS have almost invariably better outcomes than those who are HIV positive with clinical progression of a given disease. The occurrence of IRIS does not require any modification in the treatment of OIs. Maintenance treatment for OIs should not be changed and previously completed OI treatment (e.g., for tuberculosis) should not be reinitiated. Similarly, the dosages of chronic suppressive treatment for an OI should not be increased.


  Prevention of IRIS Top


Diagnosis of IRIS requires a high index of suspicion. Detailed clinical history should be taken in patients suspected to have IRIS, which includes the following:

Symptoms: fever, cough or any specific symptoms; history of OIs: including recently diagnosed as well as past OIs; treatment of OIs: date of initiation, duration of therapy, clinical response, adherence, defaulter, resistance; ART initiation: date, regimen, adherence, prior history of ART, toxicity, any drug interaction; CD4 count and HIV viral load prior to ART initiation.

Look for the vital signs, including temperature, heart rate, blood pressure and respiratory rate. Perform a careful and thorough physical examination based on symptoms and suspicion of systems involved. Ophthalmologic examination should be included in all patients.

The following investigations should be considered before starting ART: Complete blood count with differential, ESR, serum electrolytes, liver function tests and renal function tests, CD4 count and HIV viral load, chest X-ray, Mantoux (tuberculin) test, sputum stain and culture and ultrasonography of abdomen. In a suspected case, even an initially negative Mantoux test becoming positive could be suggestive of IRIS.

Patients who are started on ART having CD4 count of less than 100 cells/µl require close clinical monitoring during the first weeks of ART. Similarly, they should be counseled about the risk of development of IRIS to avoid being discouraged and defaulting on therapy as development of IRIS suggests increase in the immunity and is a good sign unless life-threatening.

 
  References Top

1.Stoll M, Schmidt RE. Immune restoration inflammatory syndromes: Apparently paradoxical clinical events after the initiation of HAART. Curr HIV/AIDS Rep 2004;1:122-7.  Back to cited text no. 1  [PUBMED]  
2.French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004;18:1615-27.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Race EM, Adelson-Mitty J, Krigel GR, Barlam TF, Reimann KA, Letvin NL, et al . Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998;351:252-5.  Back to cited text no. 3    
4.Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998;158:157-61.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]
5.Fox PA, Barton SE, Francis N, Youle M, Henderson DC, Pillay D, et al . Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease. HIV Med 1999;1:10-8.  Back to cited text no. 5    
6.DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1 infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000;133:447-54.   Back to cited text no. 6  [PUBMED]  [FULLTEXT]
7.French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, et al . Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000;1:107-15.  Back to cited text no. 7    
8.Hoffmann C, Degen O, Horst HA, van Lunzen J, Stellbrink HJ. Immune reconstitution in severely immunocompromized patients initiating HAART-the critical first months. Deutscher AIDS-Kongress: Essen; 1999. p. F1088.  Back to cited text no. 8    
9.Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordana TP, White AC Jr, et al . Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005;19:399-406.  Back to cited text no. 9    
10.Foulon G, Wislez M, Naccache JM, Blabc FX, Rabbat A, Israel-Biet D, et al . Sarcoidosis in HIV-infected patients in the era of highly active antiretroviral therapy. Clin Infect Dis 2004;38:418-25.  Back to cited text no. 10    
11.Navas E, Martin-Davila P, Moreno L, Pintado V, Casado JL, Fortun J, et al . Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002;162:97-9.   Back to cited text no. 11    
12.Foudraine NA, Hovenkamp E, Notermans DW, Meenhorst PL, Klein MR, Lange JM, et al . Immunopathology as a result of HAART in HIV-1-infected patients. AIDS 1999;13:177-84.  Back to cited text no. 12    
13.Boelaert JR, Goddeeris KH, Vanopdenbosch LJ, Casselman JW. Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy. AIDS 2004;18:1223-4.   Back to cited text no. 13  [PUBMED]  [FULLTEXT]
14.Wislez M, Bergot E, Antoine M, Parrot A, Carette MF, Mayaud C, et al . Acute respiratory failure following HARRT introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2001;164:847-51.  Back to cited text no. 14    
15.Robinson MR, Reed G, Csaky KG, Polis MA, Whitcup SM. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. Am J Opthalmol 2000;130:49-56.  Back to cited text no. 15  [PUBMED]  [FULLTEXT]
16.World Health Organization: Regional Office for South-East Asia, New Delhi. The Use of Antiretroviral therapy: A simplified approach for resource-constrained countries. July 2002.   Back to cited text no. 16    
17.Shelburne SA 3rd, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003;5:67-79.  Back to cited text no. 17  [PUBMED]  


    Tables

[Table - 1]

This article has been cited by
1 The immune reconstitution inflammatory syndrome
Bosamiya, S.
Indian Journal of Dermatology. 2011; 56(5): 476-479
[Pubmed]
2 Immune reconstitution inflammatory syndrome | [Síndrome inflamatória da reconstituição imunológica]
Nadal, S.R., Manzione, C.R.
Revista Brasileira de Coloproctologia. 2009; 29(1): 125-128
[Pubmed]
3 Oral lesions and immune reconstitution syndrome in HIV+/AIDS patients receiving highly active antiretroviral therapy. Epidemiological evidence
Gaitan Cepeda, L.A., Ceballos Salobreña, A., López Ortega, K., Arzate Mora, N., Jiménez Soriano, Y.
Medicina Oral, Patologia Oral y Cirugia Bucal. 2008; 13(2): 85-93
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow